Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Delaware for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Delaware only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Delaware (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Nouman Asif (NPI 1790947174)

Field	Value
Entity Type	Individual
Organization	Nouman Asif
Address	18947 John J Williams Hwy
City	Rehoboth Beach
State	DE
ZIP	19971
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 27, 2008

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

This provider is an established Hematology & Oncology physician in REHOBOTH BEACH, DE with Total Medicare revenue of $1.5M and no Medicaid billing on file, meaning the practice is effectively single-payer (Medicare) in the available claims data. The NPI was enumerated 2008-06-27 (~18 years ago), indicating an enduring presence in the market that likely supports steady referral patterns and longitudinal care delivery.

Revenue is highly concentrated in a small set of drug/infusion codes: the precomputed top 3 Medicare codes by revenue account for 60.7% of this provider's total Medicare revenue, led by J9271 ($507.4K, 36.7%), followed by J0897 ($204.1K, 14.7%) and J1568 ($128.4K, 9.3%). This concentration shows dependence on a few high-revenue biologics and infused therapies for the majority of billed Medicare dollars.

The specific code mix points to an infusion-based oncology practice that delivers both anti-cancer immunotherapy and supportive care: J9271 (pembrolizumab) is the top revenue driver, J0897 (denosumab) is the second largest, and chemotherapy administration codes such as 96413 and infusion administration codes 96365/96367/96375 are present, together with frequent laboratory monitoring codes (85025, 80053). Concurrent use of iron therapies (J1437, J1439) and erythropoiesis-stimulating agent J0881 suggests active management of treatment-related anemia and supportive oncology services.

Competitive standing varies by code: J9271 ranks #966 of 1841 (47th percentile) and is categorized as "typical, unremarkable volume for this code," indicating mid-pack pembrolizumab activity nationally; by contrast J0897 ranks #913 of 10057 (91th percentile) signaling relatively high denosumab activity among peers even though the dataset labels the volume as "typical, unremarkable." J1568 ranks #138 of 381 (64th percentile) and is also described as "typical, unremarkable volume."

Office evaluation-and-management volumes are unusually high for an oncology practice: 99213 (1K claims, $65.6K) ranks in the 99th percentile and is labeled an "extreme outlier, far above typical national volume for this code," while 99214 (728 claims, $71.3K) ranks in the 95th percentile and is described as "notably above typical national volume." These elevated E/M volumes imply a high clinic throughput or intensive follow-up schedule that materially supplements drug and infusion revenue.

Several ancillary/supportive services are also statistically elevated, consistent with active infusion practice workflows: 96372 ranks in the 99th percentile and is labeled "notably above typical national volume," 99195 ranks in the 99th percentile ("typical, unremarkable volume" in the dataset) for therapeutic phlebotomy, and lab codes such as 85025 and 36415 appear in the high percentiles (both described as "typical, unremarkable volume" but with high absolute claim counts). Together these point to frequent injections, blood draws, and lab monitoring supporting infusion care.

The payer mix is effectively mono‑payer in the available records: Medicare accounts for the entirety of reported public-payer revenue ($1.5M) and there is none for Medicaid (no Medicaid billing on file). This absence of Medicaid volume has operational implications for contracting and revenue diversification and suggests the provider either does not enroll in Medicaid, does not treat many Medicaid patients, or bills them through other arrangements not visible in this dataset.

Clinical implications from the drug mix include focus areas that affect referral and downstream services: heavy use of pembrolizumab (J9271) and chemotherapy administration (96413) is consistent with active oncology treatment, while denosumab (J0897) and iron therapies (J1437, J1439) reflect bone-health and anemia management services that increase ancillary visit and infusion demand. These service-line patterns, combined with long tenure (~18 years) and concentrated Medicare revenue, characterize the provider as a stable, infusion-centric oncology practice with high clinic throughput and limited Medicaid engagement.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

68 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	11,800	$40	$507.4K
J0897	Injection, denosumab, 1 mg	11,340	$20	$204.1K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,890	$30	$128.4K
J1437	Injection, ferric derisomaltose, 10 mg	5,400	$20	$86.4K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	39,190	$1	$78.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	730	$100	$71.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,030	$60	$65.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	450	$100	$46.7K
85025	A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a…	2,660	$10	$21.2K
J1439	Injection, ferric carboxymaltose, 1 mg	21,000	$1	$21K

Showing 1–10 of 68

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 68 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Delaware Distribution

Nouman Asif — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Delaware

Full comparison — all codes billed, vs. state median

68 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	10	17,600	$40	$992.4K
J1568	2	10	2,660	$30	$146.7K
J0897	11	60	3,360	$20	$132.9K
J3490	2	10	50	$990	$65.2K
J0881	2	10	25,410	$1	$57.7K
J1437	2	10	1,800	$20	$47.1K
96413	8	30	280	$100	$36.6K
J9217	20	30	160	$130	$31.1K
99214	200	1,830	150	$80	$25.5K
96401	18	30	110	$60	$18.4K

Showing 1–10 of 68

Related Providers

Other providers that share a Tax Identification Number (TIN) with Nouman Asif, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Maryland Oncology Hematology P.A.	MD	Hematology & Oncology Physician	$0	$4.6M
Kashif Ali	MD	Hematology & Oncology Physician	$3.6M	$0
Andrew Mener	MD	Hematology & Oncology Physician	$3.5M	$0
Jason Taksey	MD	Medical Oncology Physician	$3.3M	$0
Frederick Min	MD	Hematology & Oncology Physician	$3.2M	$0
Mohit Narang	MD	Medical Oncology Physician	$3M	$0
Frederick Smith	MD	Medical Oncology Physician	$2.7M	$0
Deepnarayan Tiwarri	MD	Hematology & Oncology Physician	$2.6M	$0
Amr Hegazi	MD	Hematology & Oncology Physician	$2.3M	$0
Edward Lee	MD	Medical Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Nouman Asif, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Coastal Kids Pediatric Dentistry, LLC	DE	Pediatric Dentistry	$0	$9.7M
Beacon Pediatrics LLC	DE	Pediatrics Physician	$0	$3.7M
Ams Of Delaware, LLC	DE	Substance Use Disorder Rehabilitation Hospital Unit	$123.6K	$3.3M
Delaware Eye Surgery Center, LLC	DE	Ambulatory Surgical Clinic/Center	$1.3M	$20.1K
Charles Curry	DE	Ophthalmology Physician	$605.3K	$0
Rehoboth Beach Volunteer Fire Co., Inc.	DE	Ambulance	$459.2K	$62.8K
Scott Fudemberg	DE	Ophthalmology Physician	$353.5K	$0
Arthur Belson	DE	Ophthalmology Physician	$316.3K	$0
Matthew Tulloch	DE	Family Medicine Physician	$257K	$0
Laurie Conti	DE	Optometrist	$203.8K	$44.9K

Nouman Asif — Billing Profile & Reimbursement Data

Sign up for Nouman Asif — Billing Profile & Reimbursement Data policy alerts

Nouman Asif — Billing Profile & Reimbursement Data

Sign up for Nouman Asif — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References